AC50 (functional)
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active
|
ChEMBL.
|
No reference
|
AC50 (functional)
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2d6 Compounds with AC50 equal or less than 10 uM are considered active
|
ChEMBL.
|
No reference
|
AC50 (functional)
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp1a2 Compounds with AC50 equal or less than 10 uM are considered active
|
ChEMBL.
|
No reference
|
AC50 (functional)
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c19 Compounds with AC50 equal or less than 10 uM are considered active
|
ChEMBL.
|
No reference
|
AC50 (functional)
|
|
PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp3a4 Compounds with AC50 equal or less than 10 uM are considered active
|
ChEMBL.
|
No reference
|
Activity (binding)
|
|
Inhibition of human liver MAOB
|
ChEMBL.
|
18834112
|
Activity (functional)
|
|
Bactericidal activity against 12-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 11 days by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (functional)
|
|
Antifungal activity against Candida albicans
|
ChEMBL.
|
412966
|
Activity (ADMET)
|
|
Toxicity in albino mouse assessed as mortality at 50 to 100 mg/kg indomethacin mol equivalent, ip measured after 24 hrs
|
ChEMBL.
|
25937011
|
Activity (functional)
|
|
Bactericidal activity against 19-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 4 days by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (functional)
|
|
Antifungal activity against Candida albicans ATCC 10231 up to 1.25 mg/ml after 24 hr by broth microdilution method
|
ChEMBL.
|
No reference
|
Activity (functional)
|
|
Antibacterial activity against Mycobacterium tuberculosis infected in Hartley guinea pig spleen assessed as reduction in bacterial load at 100 mg/kg
|
ChEMBL.
|
18694944
|
Activity (functional)
|
|
Bactericidal activity against 26-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 11 days by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (functional)
|
|
Antibacterial activity against Mycobacterium tuberculosis infected in Hartley guinea pig lung assessed as reduction in development of new secondary lesions at 100 mg/kg after 4 weeks by histological analysis relative to control
|
ChEMBL.
|
18694944
|
Activity (functional)
|
|
Antimicrobial activity against Trichomonas
|
ChEMBL.
|
11076565
|
Activity (functional)
|
|
Bactericidal activity against 19-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 1 day by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (functional)
|
|
Bactericidal activity against 26-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 4 days by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (functional)
|
|
Antifungal activity against Cryptococcus neoformans after 48 hrs by broth microdilution technique
|
ChEMBL.
|
18061311
|
Activity (functional)
|
|
Antibacterial activity against Mycobacterium tuberculosis infected in Hartley guinea pig lung assessed as reduction in bacterial load at 100 mg/kg
|
ChEMBL.
|
18694944
|
Activity (functional)
|
|
Bactericidal activity against 5-day old actively replicating Mycobacterium tuberculosis H37Rv in aerobic condition at 8 ug/ml by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (functional)
|
|
Growth inhibition of Escherichia coli CC104 expressing rdxA after 16 hrs relative to Escherichia coli with pBSK
|
ChEMBL.
|
17158936
|
Activity (functional)
|
|
Bactericidal activity against 12-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 1 day by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (functional)
|
|
Antimycobacterial activity against 30 day old non-replicating dormant cultures of Mycobacterium tuberculosis H37Rv assessed as reduction of bacterial viability measured after 11 days by resazurin reduction assay
|
ChEMBL.
|
19827833
|
Activity (functional)
|
|
Bactericidal activity against 19-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 11 days by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (functional)
|
|
Antibacterial activity against Mycobacterium tuberculosis infected in Hartley guinea pig lung assessed as reduction in bacteria induced progression of inflammation at 100 mg/kg after 4 weeks by histological analysis relative to control
|
ChEMBL.
|
18694944
|
Activity (functional)
|
|
Bactericidal activity against 12-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 4 days by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (binding)
|
|
Inhibition of human recombinant MAOB at 100 uM by fluorimetric method
|
ChEMBL.
|
18834112
|
Activity (functional)
|
|
Bactericidal activity against 26-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 1 day by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (functional)
|
|
Antimycobacterial activity against 30 day old non-replicating dormant cultures of Mycobacterium tuberculosis H37Rv assessed as revival of bacterial viability exposed for 11 days measured after 30 days post exposure by resazurin reduction assay
|
ChEMBL.
|
19827833
|
Activity (functional)
|
|
Antifungal activity against Candida albicans after 48 hrs by broth microdilution technique
|
ChEMBL.
|
18061311
|
Activity (ADMET)
|
|
Toxicity in albino mouse assessed as appearance of toxic symptoms at 50 to 100 mg/kg indomethacin mol equivalent, ip measured after 24 hrs
|
ChEMBL.
|
25937011
|
Activity (functional)
|
= -1.61
|
Mutagenic activity of the compound was tested in an Ames test on S. typhimurium TA98; Activity is log of revertants/nmol
|
ChEMBL.
|
1995902
|
Activity (functional)
|
0
|
Growth inhibition of Escherichia coli CC104 expressing rdxA after 16 hrs relative to Escherichia coli with pBSK
|
ChEMBL.
|
17158936
|
Activity (functional)
|
0
|
Bactericidal activity against 5-day old actively replicating Mycobacterium tuberculosis H37Rv in aerobic condition at 8 ug/ml by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (functional)
|
0
|
Bactericidal activity against 19-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 1 day by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (functional)
|
0
|
Bactericidal activity against 19-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 4 days by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (functional)
|
0
|
Bactericidal activity against 19-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 11 days by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (functional)
|
0
|
Bactericidal activity against 26-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 1 day by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (functional)
|
0
|
Bactericidal activity against 26-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 4 days by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (functional)
|
0
|
Bactericidal activity against 26-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 11 days by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (functional)
|
0
|
Bactericidal activity against 12-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 1 day by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (functional)
|
0
|
Bactericidal activity against 12-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 4 days by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (functional)
|
0
|
Bactericidal activity against 12-day old non-replicating Mycobacterium tuberculosis H37Rv in anaerobic condition at 8 ug/ml after 11 days by Wayne dormancy culture model
|
ChEMBL.
|
17242153
|
Activity (functional)
|
0
|
Antimicrobial activity against Fusobacterium nucleatum biofilms assessed as decrease in viable cell count at 2 uM after 30 mins
|
ChEMBL.
|
17325219
|
Activity (binding)
|
0
|
Inhibition of Giardia lamblia recombinant nitroreductase 1 (EAA43030.1) expressed in Escherichia coli at 5 uM
|
ChEMBL.
|
17438059
|
Activity (functional)
|
= 15
|
Value is expressed as the ratio of (T. foetus infected) animals cured / total number(15) infected at day 1 post treatment after 4 days of treatment
|
ChEMBL.
|
4067993
|
Activity (functional)
|
= 15
|
Value is expressed as the ratio of (T. foetus infected) animals cured / total number(15) infected at day 4 post treatment after 4 days of treatment
|
ChEMBL.
|
4067993
|
Activity (functional)
|
= 0 %
|
Antitrichomonal activity against metronidazole-sensitive Trichomonas vaginalis ATCC 30236 clinical isolate trophozoites assessed as parasite viability at 100 uM after 24 hrs by trypan blue dye based hemocytometry
|
ChEMBL.
|
27020521
|
Activity (ADMET)
|
= 29.2 %
|
Toxicity in CF1 mouse assessed as change in sleeping time at 300 mg/kg, po administered 30 mins prior to hexobarbital sodium challenge relative to vehicle-treated control
|
ChEMBL.
|
211235
|
Activity (functional)
|
= 36 %
|
Antimicrobial activity against Mycobacterium tuberculosis H37Rv at assessed as growth inhibition at 10 mg/kg following 24 days oxygen depletion by Wayne method relative to control
|
ChEMBL.
|
18268091
|
Activity (ADMET)
|
>= 68 %
|
Cytotoxicity against human HepG2 cells assessed as cell viability at 100 uM after 48 hrs by MTT assay
|
ChEMBL.
|
23644202
|
Activity (ADMET)
|
= 92.5 %
|
Cytotoxicity against human HepG2 cells assessed as viable cells at 3.13 uM after 48 hrs by MTT assay
|
ChEMBL.
|
22236470
|
Activity (ADMET)
|
= 95 %
|
Cytotoxicity against human HepG2 cells assessed as cell viability at 3.13 uM after 48 hrs by MTT assay
|
ChEMBL.
|
22658085
|
Activity (functional)
|
= 99.5 %
|
Trichomonacidal activity against Trichomonas vaginalis JH31A at 0.5 ug/ml after 48 hrs by Neubauer chamber analysis relative to control
|
ChEMBL.
|
24513185
|
Activity (functional)
|
= 100 %
|
Antimicrobial activity against Trichomonas vaginalis G3 assessed as parasite death at 1 uM after 24 hrs
|
ChEMBL.
|
17371810
|
Activity (functional)
|
= 100 %
|
Antimicrobial activity against Trichomonas vaginalis G3 assessed as parasite death at 1 uM after 24 hrs
|
ChEMBL.
|
17371810
|
Activity (ADMET)
|
= 100 %
|
Cytotoxicity against human MCF7 cells assessed as cell viability up to 100 uM after 48 hrs by MTT assay
|
ChEMBL.
|
20961670
|
Activity (functional)
|
= 100 %
|
Cytotoxicity against Trichomonas vaginalis TV-VP60 at 50 uM after 24 hrs by trypan blue exclusion assay
|
ChEMBL.
|
21105684
|
Activity (functional)
|
= 6.9 log CFU
|
Viable M. tuberculosis in spleen of infected Mice after an 8-day drug treatment; Dose is 150 mg/kg
|
ChEMBL.
|
15456272
|
Activity (functional)
|
= 8.5 log CFU
|
Viable M. tuberculosis in lungs of infected Mice after an 8-day drug treatment; Dose is 150 mg/kg
|
ChEMBL.
|
15456272
|
Activity (functional)
|
= 6 mm
|
Antibacterial activity against Helicobacter pylori isolate assessed as inhibition zone diameter at 0.5 ug/disk after 3-5 days by paper disk diffusion assay
|
ChEMBL.
|
18442909
|
Activity (functional)
|
= 6 mm
|
Antibacterial activity against Helicobacter pylori isolate assessed as inhibition zone diameter at 1 ug/disk after 3-5 days by paper disk diffusion assay
|
ChEMBL.
|
18442909
|
Activity (functional)
|
= 7.5 mm
|
Antibacterial activity against Helicobacter pylori isolate assessed as inhibition zone diameter at 2 ug/disk after 3-5 days by paper disk diffusion assay
|
ChEMBL.
|
18442909
|
Activity (functional)
|
= 8.75 mm
|
Antibacterial activity against Helicobacter pylori isolate assessed as inhibition zone diameter at 4 ug/disk after 3-5 days by paper disk diffusion assay
|
ChEMBL.
|
18442909
|
Activity (functional)
|
= 11 mm
|
Antibacterial activity against metronidazole-resistant Helicobacter pylori assessed as inhibition zone diameter at 8 ug/disk after 3-5 days by paper disk diffusion assay
|
ChEMBL.
|
18442909
|
Activity (functional)
|
= 12 mm
|
Antibacterial activity against metronidazole-resistant Helicobacter pylori assessed as inhibition zone diameter at 16 ug/disk after 3-5 days by paper disk diffusion assay
|
ChEMBL.
|
18442909
|
Activity (functional)
|
= 14 mm
|
Antibacterial activity against metronidazole-resistant Helicobacter pylori assessed as inhibition zone diameter at 32 ug/disk after 3-5 days by paper disk diffusion assay
|
ChEMBL.
|
18442909
|
Activity (functional)
|
= 16.3 mm
|
Antibacterial activity against Helicobacter pylori isolate assessed as inhibition zone diameter at 8 ug/disk after 3-5 days by paper disk diffusion assay
|
ChEMBL.
|
18442909
|
Activity (functional)
|
= 18 mm
|
Antibacterial activity against metronidazole-sensitive Helicobacter pylori assessed as inhibition zone diameter at 8 ug/disk after 3-5 days by paper disk diffusion assay
|
ChEMBL.
|
18442909
|
Activity (functional)
|
= 18.4 mm
|
Antibacterial activity against Helicobacter pylori isolate assessed as inhibition zone diameter at 16 ug/disk after 3-5 days by paper disk diffusion assay
|
ChEMBL.
|
18442909
|
Activity (functional)
|
= 20.7 mm
|
Antibacterial activity against Helicobacter pylori isolate assessed as inhibition zone diameter at 32 ug/disk after 3-5 days by paper disk diffusion assay
|
ChEMBL.
|
18442909
|
Activity (functional)
|
= 23 mm
|
Antibacterial activity against metronidazole-sensitive Helicobacter pylori assessed as inhibition zone diameter at 16 ug/disk after 3-5 days by paper disk diffusion assay
|
ChEMBL.
|
18442909
|
Activity (functional)
|
= 27 mm
|
Antibacterial activity against metronidazole-sensitive Helicobacter pylori assessed as inhibition zone diameter at 32 ug/disk after 3-5 days by paper disk diffusion assay
|
ChEMBL.
|
18442909
|
Activity (ADMET)
|
> 200 ug ml-1
|
Cytotoxicity against human HepG2 cells assessed as concentration required to decrease cell viability incubated for 24 hrs followed by compound washout measured after 18 hrs by resazurin dye-based assay
|
ChEMBL.
|
24360560
|
Activity (ADMET)
|
= 869.33 uM
|
Cytotoxicity against Homo sapiens (human) Hep2 cells assessed as concentration at which cell growth as in negative control after 48 hr by hemocytometer
|
ChEMBL.
|
No reference
|
Amount excreted (ADMET)
|
= 25 %
|
The amount of the unchanged form of compound detected in the urine samples collected at 0-18 h after the treatment by HPLC technique
|
ChEMBL.
|
3959031
|
Amount excreted (ADMET)
|
= 30.5 %
|
The amount of unchanged compound detected in urine collected at 0-18 h after treatment
|
ChEMBL.
|
3959031
|
Amount excreted (ADMET)
|
= 49.2 %
|
The amount of unchanged compound in urine collected at 0-36 h after treatment
|
ChEMBL.
|
3959031
|
Amount excreted (ADMET)
|
= 49.2 %
|
The amount of unchanged compound in urine collected at 0-54 h after treatment
|
ChEMBL.
|
3959031
|
Amount excreted (ADMET)
|
= 49.2 %
|
The amount of unchanged compound in urine collected at 0-72 h after treatment
|
ChEMBL.
|
3959031
|
AUC (ADMET)
|
|
AUC (area under curve) after oral dosing by gavage needle at 30 mg/kg in C57BL/6NTac female mice; Not checked
|
ChEMBL.
|
12213071
|
Biliary excretion (ADMET)
|
= 6.77 %
|
Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.
|
ChEMBL.
|
3806622
|
Biliary excretion (ADMET)
|
= 12.46 %
|
Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.
|
ChEMBL.
|
3806622
|
Biliary excretion (ADMET)
|
= 16.77 %
|
Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.
|
ChEMBL.
|
3806622
|
Biliary excretion (ADMET)
|
= 19.69 %
|
Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.
|
ChEMBL.
|
3806622
|
Biliary excretion (ADMET)
|
= 22.31 %
|
Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.
|
ChEMBL.
|
3806622
|
Biliary excretion (ADMET)
|
= 24.55 %
|
Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.
|
ChEMBL.
|
3806622
|
C1.6 (functional)
|
= 13.3 mM
|
Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia
|
ChEMBL.
|
8308864
|
C1.6 (functional)
|
= 17.3 mM
|
Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6
|
ChEMBL.
|
8308864
|
C50 (functional)
|
= 6.5 mM
|
Concentration required to kill 50 % of the cells after ca. 7 days aerobic exposure.
|
ChEMBL.
|
No reference
|
C50 (binding)
|
= 3200 uM
|
Concentration required for 50% decrease in fluorescence of ethidium bromide bound to calf thymus DNA. at 600 nm
|
ChEMBL.
|
No reference
|
CL (ADMET)
|
= 0.7 ml/min.kg
|
Hepatic clearance in human
|
ChEMBL.
|
20070106
|
CL (ADMET)
|
= 0.85 ml/min.kg
|
Total body clearance in human
|
ChEMBL.
|
19445515
|
CL (ADMET)
|
= 0.85 ml/min.kg
|
Total clearance in human
|
ChEMBL.
|
20070106
|
CL_renal (ADMET)
|
= 0.19 ml/min.kg
|
Renal clearance in human
|
ChEMBL.
|
19445515
|
CL_renal (ADMET)
|
= 0.2 ml/min.kg
|
Renal clearance in human
|
ChEMBL.
|
20070106
|
Cmax (ADMET)
|
|
Maximum plasma concentration (Cmax) after oral dosing by gavage needle at 30 mg/kg in C57BL/6NTac female mice; Not checked
|
ChEMBL.
|
12213071
|
Concentration (functional)
|
0 ug ml-1
|
Antiprotozoal activity measured as the conc for >95% inhibition of Trichomonas foetus; ND denotes no data
|
ChEMBL.
|
6834379
|
Concentration (functional)
|
0 ug ml-1
|
Antiprotozoal activity measured as the conc for 95-25% inhibition of Entamoeba histolytica; ND denotes no data
|
ChEMBL.
|
6834379
|
Concentration (functional)
|
0 ug ml-1
|
Antiprotozoal activity measured as the conc for <25% inhibition of Entamoeba histolytica; ND denotes no data
|
ChEMBL.
|
6834379
|
Concentration (functional)
|
= 0.06 ug ml-1
|
Antiprotozoal activity measured as the conc for <25% inhibition of Trichomonas vaginalis
|
ChEMBL.
|
6834379
|
Concentration (functional)
|
= 0.06 ug ml-1
|
Antiprotozoal activity measured as the conc for <25% inhibition of Trichomonas vaginalis
|
ChEMBL.
|
6834379
|
Concentration (functional)
|
= 0.12 ug ml-1
|
Antiprotozoal activity measured as the conc for 95-25% inhibition of Trichomonas vaginalis
|
ChEMBL.
|
6834379
|
Concentration (functional)
|
= 0.12 ug ml-1
|
Antiprotozoal activity measured as the conc for <25% inhibition of Trichomonas foetus
|
ChEMBL.
|
6834379
|
Concentration (functional)
|
= 0.12 ug ml-1
|
Antiprotozoal activity measured as the conc for >95% inhibition of Entamoeba histolytica
|
ChEMBL.
|
6834379
|
Concentration (functional)
|
= 0.12 ug ml-1
|
Antiprotozoal activity measured as the conc for 95-25% inhibition of Trichomonas vaginalis
|
ChEMBL.
|
6834379
|
Concentration (functional)
|
= 0.12 ug ml-1
|
Antiprotozoal activity measured as the conc for >95% inhibition of Entamoeba histolytica
|
ChEMBL.
|
6834379
|
Concentration (functional)
|
= 0.25 ug ml-1
|
Antiprotozoal activity measured as the conc for >95% inhibition of Trichomonas vaginalis
|
ChEMBL.
|
6834379
|
Concentration (functional)
|
= 0.25 ug ml-1
|
Antiprotozoal activity measured as the conc for 95-25% inhibition of Trichomonas foetus
|
ChEMBL.
|
6834379
|
Concentration (functional)
|
= 0.25 ug ml-1
|
Antiprotozoal activity measured as the conc for 100% inhibition of Entamoeba histolytica
|
ChEMBL.
|
6834379
|
Concentration (functional)
|
= 0.25 ug ml-1
|
Antiprotozoal activity measured as the conc for >95% inhibition of Trichomonas vaginalis
|
ChEMBL.
|
6834379
|
Concentration (functional)
|
= 0.25 ug ml-1
|
Antiprotozoal activity measured as the conc for 100% inhibition of Entamoeba histolytica
|
ChEMBL.
|
6834379
|
Concentration (functional)
|
= 0.5 ug ml-1
|
Antiprotozoal activity measured as the conc for 100% inhibition of Trichomonas vaginalis
|
ChEMBL.
|
6834379
|
Concentration (functional)
|
= 0.5 ug ml-1
|
Antiprotozoal activity measured as the conc for 100% inhibition of Trichomonas foetus
|
ChEMBL.
|
6834379
|
Concentration (functional)
|
= 0.5 ug ml-1
|
Antiprotozoal activity measured as the conc for 100% inhibition of Trichomonas vaginalis
|
ChEMBL.
|
6834379
|
CT10 (ADMET)
|
= 100 mM-hr
|
Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition
|
ChEMBL.
|
8308864
|
Cytocidal activity (functional)
|
= 98.19 %
|
In vitro cytocidal activity of the compound against Trichomonas vaginalis at a dose of 0.5 mg/ml after 24 hours
|
ChEMBL.
|
16005626
|
Cytocidal activity (functional)
|
= 98.19 %
|
In vitro cytocidal activity of the compound against Trichomonas vaginalis at a dose of 0.5 mg/ml after 24 hours
|
ChEMBL.
|
16005626
|
Cytocidal activity (functional)
|
= 98.79 %
|
In vitro cytocidal activity of the compound against Trichomonas vaginalis at a dose of 0.5 mg/ml after 48 hours
|
ChEMBL.
|
16005626
|
Cytocidal activity (functional)
|
= 98.7900000000001 %
|
In vitro cytocidal activity of the compound against Trichomonas vaginalis at a dose of 0.5 mg/ml after 48 hours
|
ChEMBL.
|
16005626
|
Cytocidal activity (functional)
|
= 99.18 %
|
In vitro cytocidal activity of the compound against Trichomonas vaginalis at a dose of 1 mg/mL after 24 hours
|
ChEMBL.
|
16005626
|
Cytocidal activity (functional)
|
= 99.18 %
|
In vitro cytocidal activity of the compound against Trichomonas vaginalis at a dose of 1 mg/mL after 24 hours
|
ChEMBL.
|
16005626
|
Cytocidal activity (functional)
|
= 99.63 %
|
In vitro cytocidal activity of the compound against Trichomonas vaginalis at a dose of 2 mg/ml after 24 hours
|
ChEMBL.
|
16005626
|
Cytocidal activity (functional)
|
= 99.63 %
|
In vitro cytocidal activity of the compound against Trichomonas vaginalis at a dose of 2 mg/ml after 24 hours
|
ChEMBL.
|
16005626
|
Cytocidal activity (functional)
|
= 99.72 %
|
In vitro cytocidal activity of the compound against Trichomonas vaginalis at a dose of 1 mg/mL after 48 hours
|
ChEMBL.
|
16005626
|
Cytocidal activity (functional)
|
= 99.7200000000001 %
|
In vitro cytocidal activity of the compound against Trichomonas vaginalis at a dose of 1 mg/mL after 48 hours
|
ChEMBL.
|
16005626
|
Cytocidal activity (functional)
|
= 100 %
|
In vitro cytocidal activity of the compound against Trichomonas vaginalis at a dose of 2 mg/ml after 48 hours
|
ChEMBL.
|
16005626
|
Cytocidal activity (functional)
|
= 100 %
|
In vitro cytocidal activity of the compound against Trichomonas vaginalis at a dose of 2 mg/ml after 48 hours
|
ChEMBL.
|
16005626
|
delta logD (ADMET)
|
= 0
|
Delta logD (logD6.5 - logD7.4)
|
ChEMBL.
|
10891117
|
Dose (functional)
|
= 10 mg kg-1 day-1
|
Lowest active dose which cured rats with Entamoeba histolytica cecal infection was measured
|
ChEMBL.
|
7359534
|
Dose (functional)
|
= 10 mg kg-1 day-1
|
Lowest active dose which cured hamsters with Entamoeba histolytica hepatic infection was measured
|
ChEMBL.
|
7359534
|
Dose (functional)
|
= 10 mg kg-1 day-1
|
Lowest active dose which cured rats with Entamoeba histolytica cecal infection was measured
|
ChEMBL.
|
7359534
|
Dose (functional)
|
= 10 mg kg-1 day-1
|
Lowest active dose which cured hamsters with Entamoeba histolytica hepatic infection was measured
|
ChEMBL.
|
7359534
|
EC50 (functional)
|
= 7 ug ml-1
|
Antimicrobial activity against Escherichia coli JM109 transformed with Entamoeba histolytica NTR1 after 16 hrs
|
ChEMBL.
|
19015349
|
EC50 (functional)
|
= 8 ug ml-1
|
Antimicrobial activity against Escherichia coli JM109 transformed with Entamoeba histolytica NTR2 after 16 hrs
|
ChEMBL.
|
19015349
|
EC50 (functional)
|
= 25 ug ml-1
|
Antimicrobial activity against Escherichia coli JM109 transformed with empty vector PQE30 after 16 hrs
|
ChEMBL.
|
19015349
|
EC50 (functional)
|
= 500 ug ml-1
|
Antimicrobial activity against Escherichia coli JM109 transformed with Trichomonas vaginalis nim1 after 16 hrs
|
ChEMBL.
|
19015349
|
EC50 (functional)
|
= 750 ug ml-1
|
Antimicrobial activity against Escherichia coli JM109 transformed with Entamoeba histolytica nim1 after 16 hrs
|
ChEMBL.
|
19015349
|
EC50 (ADMET)
|
> 1000 ug ml-1
|
Cytotoxicity against human HeLa cells by MTT assay
|
ChEMBL.
|
22846917
|
EC50 (functional)
|
= 1.2 uM
|
Antiparasitic activity against Trichomonas vaginalis GT3 after 48 hr by Alamar blue assay
|
ChEMBL.
|
No reference
|
EC50 (functional)
|
= 2 uM
|
Antimicrobial activity against Entamoeba histolytica HM1 IMSS tropozoits after 48 hrs
|
ChEMBL.
|
17371810
|
EC50 (functional)
|
= 2 uM
|
Antimicrobial activity against Entamoeba histolytica HM1 IMSS tropozoits after 48 hrs
|
ChEMBL.
|
17371810
|
EC50 (functional)
|
> 500 uM
|
Antimicrobial activity against Trypanosoma brucei
|
ChEMBL.
|
20439607
|
EC50 (functional)
|
> 500 uM
|
Antimicrobial activity against Trypanosoma brucei NfxR1
|
ChEMBL.
|
20439607
|
EC50 (functional)
|
> 500 uM
|
Antimicrobial activity against Trypanosoma brucei NfxR2
|
ChEMBL.
|
20439607
|
ED50 (functional)
|
= 12.3 mg kg-1
|
Antimicrobial activity against Trichomonas vaginalis infected in sc dosed mouse
|
ChEMBL.
|
16132
|
ED50 (functional)
|
= 0.4 ug ml-1
|
In vitro anti-trichomonal activity against Trichomonas foetus-Ortho strain-2.
|
ChEMBL.
|
3543363
|
eLog D (ADMET)
|
= 0.12
|
HPLC capacity factor (k')
|
ChEMBL.
|
12061889
|
F (ADMET)
|
>= 80 %
|
Oral bioavailability in human
|
ChEMBL.
|
10891117
|
fi (ADMET)
|
= 0
|
Fraction ionized (pH 7.4)
|
ChEMBL.
|
12061889
|
fu (ADMET)
|
= 0.89
|
Unbound fraction (plasma)
|
ChEMBL.
|
12061889
|
Fu (ADMET)
|
= 0.89
|
Unbound fraction (plasma)
|
ChEMBL.
|
14971904
|
fut (ADMET)
|
= 0.609
|
Unbound fraction (tissues)
|
ChEMBL.
|
12061889
|
GI (functional)
|
= 6.64 %
|
Antibacterial activity against Escherichia coli DH5alpha assessed as growth inhibition at 50 ug/ml after 16 hrs by spectrophotometric method
|
ChEMBL.
|
24641976
|
GI (functional)
|
= 8.2 %
|
Antibacterial activity against Escherichia coli DH5alpha assessed as growth inhibition at 75 ug/ml after 16 hrs by spectrophotometric method
|
ChEMBL.
|
24641976
|
GI (functional)
|
= 14.96 %
|
Antibacterial activity against Escherichia coli DH5alpha assessed as growth inhibition at 100 ug/ml after 16 hrs by spectrophotometric method
|
ChEMBL.
|
24641976
|
GI (functional)
|
= 99 %
|
Growth inhibition of Mycobacterium tuberculosis H37Rv at >256 ug/mL
|
ChEMBL.
|
22607678
|
GI (functional)
|
= 99 %
|
Antitubercular activity against Mycobacterium tuberculosis H37Rv at > 256 ug/mL
|
ChEMBL.
|
22560587
|
Hypersensitivity factor (functional)
|
= 1
|
Aerobic cytotoxicity of the compound against UV4 cells in a growth inhibition microassay
|
ChEMBL.
|
8308864
|
Hypersensitivity factor (functional)
|
= 1
|
Aerobic cytotoxicity of the compound against murine mammary carcinoma EMT6 cells in a growth inhibition microassay
|
ChEMBL.
|
8308864
|
Hypersensitivity factor (functional)
|
= 1
|
Aerobic cytotoxicity of the compound against human melanoma FME cells in a growth inhibition microassay
|
ChEMBL.
|
8308864
|
IC50 (binding)
|
|
DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF)
|
ChEMBL.
|
No reference
|
IC50 (functional)
|
|
Antileishmanial activity against Leishmania mexicana MHOM/MX92/UAY68 after 48 hrs
|
ChEMBL.
|
20430484
|
IC50 (binding)
|
|
DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968)
|
ChEMBL.
|
No reference
|
IC50 (functional)
|
|
Antiprotozoal activity against Plasmodium berghei
|
ChEMBL.
|
18486471
|
IC50 (binding)
|
|
DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon))
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH)
|
ChEMBL.
|
No reference
|
IC50 (functional)
|
|
Antiprotozoal activity against Leishmania donovani MHOM/ET/L82/LV9
|
ChEMBL.
|
16309903
|
IC50 (binding)
|
|
DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)
|
ChEMBL.
|
No reference
|
IC50 (functional)
|
|
Antiprotozoal activity against Leishmania mexicana
|
ChEMBL.
|
18486471
|
IC50 (binding)
|
|
DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA))
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Chemokine CXCR1 (IL-8A)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4)
|
ChEMBL.
|
No reference
|
IC50 (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone)
|
ChEMBL.
|
No reference
|
IC50 (ADMET)
|
= 2.22
|
Cytotoxicity against human HeLa cells after 2 days by Alamar blue assay
|
ChEMBL.
|
19480409
|
IC50 (functional)
|
= 6.5
|
Antimicrobial activity against Trichomonas vaginalis GT3 incubated for 48 hrs followed by compound washout measured after 48 hrs
|
ChEMBL.
|
24529307
|
IC50 (functional)
|
0
|
Antiprotozoal activity against Leishmania donovani MHOM/ET/L82/LV9
|
ChEMBL.
|
16309903
|
IC50 (functional)
|
0
|
Antiprotozoal activity against Leishmania mexicana
|
ChEMBL.
|
18486471
|
IC50 (functional)
|
0
|
Antiprotozoal activity against Plasmodium berghei
|
ChEMBL.
|
18486471
|
IC50 (functional)
|
= 23 mM
|
Concentration of the compound required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay
|
ChEMBL.
|
8308864
|
IC50 (functional)
|
= 0.037 ug ml-1
|
Antiprotozoal activity against trophozoite stage of Trichomonas vaginalis GT3 assessed as growth inhibition
|
ChEMBL.
|
24468633
|
IC50 (functional)
|
= 0.04 ug ml-1
|
Antiprotozoal activity against Entamoeba histolytica HM-1:IMSS trophozoites after 48 hrs by MTT/PMS assay
|
ChEMBL.
|
11374974
|
IC50 (functional)
|
= 0.04 ug ml-1
|
Antiprotozoal activity against axenically grown trophozoites of Entamoeba histolytica HM1-IMSS after 48 hrs by MTT method
|
ChEMBL.
|
10346950
|
IC50 (functional)
|
= 0.04 ug ml-1
|
Antiprotozoal activity against clinical isolates of Entamoeba histolytica HM-1:IMSS
|
ChEMBL.
|
24099364
|
IC50 (functional)
|
= 0.04 ug ml-1
|
Antiprotozoal activity against Entamoeba histolytica HM-1:IMSS trophozoites assessed as growth inhibition compound treated for 48 hrs measured 48 hrs post wash-out by MTT assay
|
ChEMBL.
|
24974343
|
IC50 (functional)
|
= 0.12 ug ml-1
|
Antitrypanosomal activity against Trichomonas vaginalis T1
|
ChEMBL.
|
21044841
|
IC50 (functional)
|
= 0.22 ug ml-1
|
In vitro antiamoebic activity of the compound was evaluated against HK-9 strain of Entamoeba histolytica
|
ChEMBL.
|
11591499
|
IC50 (functional)
|
= 0.22 ug ml-1
|
In vitro antiamoebic activity of the compound was evaluated against HK-9 strain of Entamoeba histolytica
|
ChEMBL.
|
11591499
|
IC50 (functional)
|
= 0.23 ug ml-1
|
Antiprotozoal activity against trophozoite stage of Entamoeba histolytica HM-1:IMSS assessed as growth inhibition after 48 hrs
|
ChEMBL.
|
24468633
|
IC50 (functional)
|
= 0.33 ug ml-1
|
Tested for antiamoebic activity against HK-9 strain of E. histolytica
|
ChEMBL.
|
11055329
|
IC50 (functional)
|
= 0.33 ug ml-1
|
Tested for antiamoebic activity against HK-9 strain of E. histolytica
|
ChEMBL.
|
11055329
|
IC50 (ADMET)
|
> 1000 ug ml-1
|
Cytotoxicity against human HeLa cells
|
ChEMBL.
|
24900434
|
IC50 (ADMET)
|
> 1000 ug ml-1
|
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
|
ChEMBL.
|
24727243
|
IC50 (functional)
|
= 0.216 uM
|
Antiprotozoal activity against Trichomonas vaginalis G3 after 48 hrs
|
ChEMBL.
|
20430484
|
IC50 (functional)
|
= 0.23 uM
|
Antiprotozoal activity against Entamoeba histolytica HM-1:IMSS
|
ChEMBL.
|
26517282
|
IC50 (functional)
|
= 0.23 uM
|
Antiprotozoal activity against Entamoeba histolytica HM-1:IMSS
|
ChEMBL.
|
24502360
|
IC50 (functional)
|
= 0.236 uM
|
Antiprotozoal activity against Trichomonas vaginalis GT3 trophozoites after 48 hrs
|
ChEMBL.
|
19186059
|
IC50 (functional)
|
= 0.236 uM
|
Antiprotozoan activity against Trichomonas vaginalis GT3 trophozoites compound treated for 48 hrs measured after 48 hrs washout period
|
ChEMBL.
|
22047694
|
IC50 (functional)
|
= 0.236 uM
|
Antiprotozoal activity against trophozoite stage of Trichomonas vaginalis GT3 assessed as growth inhibition after 48 hrs by haemocytometric analysis
|
ChEMBL.
|
23731944
|
IC50 (functional)
|
= 0.286 uM
|
Antiprotozoal activity against Trichomonas vaginalis
|
ChEMBL.
|
18486471
|
IC50 (functional)
|
= 0.286 uM
|
Antiprotozoal activity against Trichomonas vaginalis
|
ChEMBL.
|
18486471
|
IC50 (functional)
|
= 0.29 uM
|
Antiparasitic activity against Trichomonas vaginalis GT3 trophozoites after 48 hrs by Hill culture method
|
ChEMBL.
|
19208443
|
IC50 (functional)
|
= 0.29 uM
|
Antimicrobial activity against Trichomonas vaginalis GT3 after 48 hrs
|
ChEMBL.
|
20674375
|
IC50 (functional)
|
= 0.29 uM
|
Antiprotozoan activity against Trichomonas vaginalis GT3 trophozoites after 48 hrs
|
ChEMBL.
|
21397502
|
IC50 (functional)
|
= 0.29 uM
|
Trichomonicidal activity against Trichomonas vaginalis GT3 compound treated for 48 hrs followed by incubation for 48 hrs in compound-free medium by cell counting
|
ChEMBL.
|
25801157
|
IC50 (functional)
|
= 0.35 uM
|
In vitro antiprotozoal activity of the compound against Entamoeba histolytica
|
ChEMBL.
|
11206455
|
IC50 (functional)
|
= 0.35 uM
|
The compound was tested in vitro against the protozoa Entamoeba histolytica, for the inhibition of tubulin polymerization in rat brain
|
ChEMBL.
|
12127542
|
IC50 (functional)
|
= 0.35 uM
|
In vitro antiprotozoal activity of the compound against Entamoeba histolytica
|
ChEMBL.
|
11206455
|
IC50 (functional)
|
= 0.35 uM
|
The compound was tested in vitro against the protozoa Entamoeba histolytica, for the inhibition of tubulin polymerization in rat brain
|
ChEMBL.
|
12127542
|
IC50 (functional)
|
= 0.35 uM
|
Antiprotozoal activity against Entamoeba histolytica HM-1:IMSS after 48 hrs
|
ChEMBL.
|
20430484
|
IC50 (functional)
|
= 0.35 uM
|
Antiprotozoan activity against Entamoeba histolytica HM1-IMSS trophozoites compound treated for 48 hrs measured after 48 hrs washout period
|
ChEMBL.
|
22047694
|
IC50 (functional)
|
= 0.3798 uM
|
Antiprotozoal activity against trophozoite stage of Entamoeba histolytica HM-1:IMSS assessed as growth inhibition after 48 hrs by haemocytometric analysis
|
ChEMBL.
|
23731944
|
IC50 (functional)
|
= 0.72 uM
|
Antiparasitic activity against Trichomonas vaginalis T1 after 24 hrs by hemocytometric analysis
|
ChEMBL.
|
20667728
|
IC50 (functional)
|
= 0.72 uM
|
Antitrypanosomal activity against Trichomonas vaginalis T1
|
ChEMBL.
|
21044841
|
IC50 (functional)
|
= 0.72 uM
|
Growth inhibition of Trichomonas vaginalis T1 after 24 hrs by hemocytometry
|
ChEMBL.
|
22579483
|
IC50 (functional)
|
= 0.77 uM
|
Antiamnesic activity against Entamoeba histolytica HM-1:IMSS trophozoites after 48 hrs by Hill culture method
|
ChEMBL.
|
19208443
|
IC50 (functional)
|
= 0.77 uM
|
Antiprotozoan activity against Entamoeba histolytica HM1-IMSS trophozoites after 48 hrs
|
ChEMBL.
|
21397502
|
IC50 (functional)
|
= 0.77 uM
|
Antimicrobial activity against Entamoeba histolytica HM-1:IMSS after 48 hrs
|
ChEMBL.
|
20674375
|
IC50 (functional)
|
= 0.771 uM
|
Antiprotozoal activity against Entamoeba histolytica
|
ChEMBL.
|
18486471
|
IC50 (functional)
|
= 0.771 uM
|
Antiprotozoal activity against Entamoeba histolytica
|
ChEMBL.
|
18486471
|
IC50 (functional)
|
= 1.16 uM
|
Inhibitory concentration of the compound against G. Lamblia (IMSS-0989) for antigiardial activity
|
ChEMBL.
|
12419387
|
IC50 (functional)
|
= 1.22 uM
|
In vitro antiprotozoal activity of the compound against Giardia lamblia
|
ChEMBL.
|
11206455
|
IC50 (functional)
|
= 1.22 uM
|
The compound was tested in vitro against the protozoa Giardia lamblia, for the inhibition of tubulin polymerization in rat brain
|
ChEMBL.
|
12127542
|
IC50 (functional)
|
= 1.23 uM
|
Antiprotozoal activity against Giardia intestinalis IMSS:0696:1 trophozoites after 48 hrs
|
ChEMBL.
|
17385912
|
IC50 (functional)
|
= 1.286 uM
|
Antiprotozoal activity against Giardia lamblia
|
ChEMBL.
|
18486471
|
IC50 (functional)
|
= 1.43 uM
|
Trichomonacidal activity against metronidazole-sensitive Trichomonas vaginalis JH31A#4 trophozoites after 24 hrs by resazurin dye based fluorescence assay
|
ChEMBL.
|
27017556
|
IC50 (functional)
|
= 1.45 uM
|
Antiamnesic activity against Entamoeba histolytica HM-1:IMSS by microdilution method
|
ChEMBL.
|
21715066
|
IC50 (functional)
|
= 1.45 uM
|
Antiamoebic activity against trophozoite stage of Entamoeba histolytica HM-1:IMSS assessed as growth inhibition after 72 hrs by microdilution method
|
ChEMBL.
|
23602620
|
IC50 (functional)
|
= 1.46 uM
|
Antiamnesic activity against Entamoeba histolytica HM-1:IMSS trophozoites after 72 hrs by microdilution method
|
ChEMBL.
|
21377771
|
IC50 (functional)
|
= 1.46 uM
|
Antiamnesic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs by eosin-staining method
|
ChEMBL.
|
22832309
|
IC50 (functional)
|
= 1.5 uM
|
Antiprotozoal activity against Entamoeba histolytica HM-1:IMSS trophozoites after 72 hrs by microdilution method
|
ChEMBL.
|
24530492
|
IC50 (functional)
|
= 1.64 uM
|
Antiamnesic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs by microdilution method
|
ChEMBL.
|
22840694
|
IC50 (functional)
|
= 1.69 uM
|
Antiamoebic activity against Entamoeba histolytica HM-1:IMSS
|
ChEMBL.
|
16495051
|
IC50 (functional)
|
= 1.69 uM
|
Antiamoebic activity against Entamoeba histolytica HM-1:IMSS
|
ChEMBL.
|
16495051
|
IC50 (functional)
|
= 1.8 uM
|
Antiamnesic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs by trypan blue exclusion assay
|
ChEMBL.
|
18384916
|
IC50 (functional)
|
= 1.8 uM
|
Antiamnesic activity against Entamoeba histolytica HMI:IMSS after 72 hrs by microdilution method
|
ChEMBL.
|
18068273
|
IC50 (functional)
|
= 1.8 uM
|
Antiamnesic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs by trypan blue exclusion method
|
ChEMBL.
|
18378360
|
IC50 (functional)
|
= 1.8 uM
|
Antiamnesic activity against Entamoeba histolytica HM-1:IMSS trophozoites after 72 hrs by microdilution method
|
ChEMBL.
|
18187238
|
IC50 (functional)
|
= 1.8 uM
|
Antiamnesic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs by microdilution assay
|
ChEMBL.
|
18068873
|
IC50 (functional)
|
= 1.8 uM
|
Antiamnesic activity against Entamoeba histolytica HM1:IMSS trophozoites after 72 hrs by microdilution method
|
ChEMBL.
|
19589625
|
IC50 (functional)
|
= 1.8 uM
|
Antiamnesic activity against Entamoeba histolytica HM-1:IMSS trophozoites after 72 hrs by microdilution technique
|
ChEMBL.
|
20122767
|
IC50 (functional)
|
= 1.8 uM
|
Antiamoebic activity against trophozoites of Entamoeba histolytica HM-1:IMSS after 72 hr by eosin stain-based spectrophotometric analysis
|
ChEMBL.
|
No reference
|
IC50 (functional)
|
= 1.8 uM
|
Antiamoebic activity against Entamoeba histolytica HM-1:IMSS trophozoite assessed as growth inhibition after 72 hr by microdilution method
|
ChEMBL.
|
No reference
|
IC50 (functional)
|
= 1.8 uM
|
Antiamnesic activity against Entamoeba histolytica HM1:IMSS after 72 hrs by microdilution method
|
ChEMBL.
|
22658085
|
IC50 (functional)
|
= 1.8 uM
|
Antiamnesic activity against Entamoeba histolytica HM1:IMSS after 72 hrs by microplate method
|
ChEMBL.
|
20719524
|
IC50 (functional)
|
= 1.8 uM
|
Antiamoebic activity against Entamoeba histolytica HM-1:IMSS trophozoites after 72 hrs by microdilution method
|
ChEMBL.
|
23644202
|
IC50 (functional)
|
= 1.8 uM
|
Antiamnesic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs by microdilution assay
|
ChEMBL.
|
20961670
|
IC50 (functional)
|
= 1.8 uM
|
Antiamnesic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs by microdilution method
|
ChEMBL.
|
22236470
|
IC50 (functional)
|
= 1.8 uM
|
Antiamnesic activity against Entamoeba histolytica HM-1:IMSS trophozoites after 72 hrs by microdilution method
|
ChEMBL.
|
22444681
|
IC50 (functional)
|
= 1.81 uM
|
Antiamnesic activity against Entamoeba histolytica HM1 IMSS after 72 hrs by serial dilution method
|
ChEMBL.
|
17513021
|
IC50 (functional)
|
= 1.81 uM
|
Antiamnesic activity against Entamoeba histolytica HM1:IMSS after 72 hrs by microplate method
|
ChEMBL.
|
18222017
|
IC50 (functional)
|
= 1.81 uM
|
Antiamnesic activity against Entamoeba histolytica HM1:IMSS after 72 hrs by microdilution method
|
ChEMBL.
|
18242785
|
IC50 (functional)
|
= 1.81 uM
|
Antiamoebic activity against trophozoite stage of Entamoeba histolytica HM-1:IMSS after 72 hrs by microdilution method
|
ChEMBL.
|
26174554
|
IC50 (functional)
|
= 1.81 uM
|
Antiameobic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs using trypan blue staining method
|
ChEMBL.
|
22309914
|
IC50 (functional)
|
= 1.82 uM
|
Antiamoebic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs
|
ChEMBL.
|
17156895
|
IC50 (functional)
|
= 1.82 uM
|
Antiamoebic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs
|
ChEMBL.
|
17156895
|
IC50 (functional)
|
= 1.84 uM
|
Antiamnesic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs by microdilution method
|
ChEMBL.
|
20696501
|
IC50 (functional)
|
= 1.92 uM
|
Inhibitory concentration of the compound against T. vaginalis (tv-43) for anti-trichomonal activity
|
ChEMBL.
|
12419387
|
IC50 (functional)
|
= 1.92 uM
|
Inhibitory concentration of the compound against T. vaginalis (tv-43) for anti-trichomonal activity
|
ChEMBL.
|
12419387
|
IC50 (functional)
|
= 2.03 uM
|
In vitro antiamoebic activity against HM-1:1MMS strain of Entamoeba histolytica
|
ChEMBL.
|
12639559
|
IC50 (functional)
|
= 2.03 uM
|
In vitro antiamoebic activity against HM-1:1MMS strain of Entamoeba histolytica
|
ChEMBL.
|
12639559
|
IC50 (functional)
|
= 2.1 uM
|
Inhibitory concentration of the compound against E. histolytica (HK-9) for antiamoebic activity
|
ChEMBL.
|
12419387
|
IC50 (functional)
|
= 2.1 uM
|
Inhibitory concentration of the compound against E. histolytica (HK-9) for antiamoebic activity
|
ChEMBL.
|
12419387
|
IC50 (functional)
|
= 2.5 uM
|
Antiprotozoal activity against Entamoeba histolytica after 24 hrs by trypan blue assay
|
ChEMBL.
|
20478706
|
IC50 (functional)
|
= 2.7 uM
|
Antitrichomonal activity against Trichomonas vaginalis TVR79 after 48 hrs by optical microscopy
|
ChEMBL.
|
19748781
|
IC50 (functional)
|
= 2.746 uM
|
Antitrichomonas activity against Trichomonas vaginalis TVR87 after 48 hrs by trypan blue staining
|
ChEMBL.
|
18590939
|
IC50 (functional)
|
= 3 uM
|
Antimicrobial activity against Trichomonas vaginalis
|
ChEMBL.
|
20185316
|
IC50 (functional)
|
= 3.2 uM
|
In vitro growth inhibition against Entamoeba histolytica
|
ChEMBL.
|
14695831
|
IC50 (functional)
|
= 3.2 uM
|
In vitro growth inhibition against Entamoeba histolytica
|
ChEMBL.
|
14695831
|
IC50 (functional)
|
= 4.16 uM
|
Trichomonicidal activity against Trichomonas vaginalis JH31A#4 trophozite assessed as inhibition of parasite growth after 24 hrs by resazurin redox dye based fluorimetric microtiter method
|
ChEMBL.
|
25771033
|
IC50 (functional)
|
= 4.4 uM
|
Antiparasitic activity against Entamoeba histolytica HK-9 strain ATCC 30015 using trypan blue staining by hemocytometer
|
ChEMBL.
|
No reference
|
IC50 (functional)
|
= 4.5 uM
|
Antiamoebic activity against trophozoite stage of Entamoeba histolytica HM-1:IMSS assessed as growth inhibition after 48 hrs by microdilution method
|
ChEMBL.
|
23787289
|
IC50 (functional)
|
= 5.8 uM
|
Antiprotozoal activity against Trichomonas vaginalis CMP
|
ChEMBL.
|
16309903
|
IC50 (functional)
|
= 5.8 uM
|
Antiprotozoal activity against Trichomonas vaginalis CMP
|
ChEMBL.
|
16309903
|
IC50 (functional)
|
= 5.82 uM
|
Antiprotozoal activity against Entamoeba histolytica Hk-9 trophozoites after 70 hrs by resazurin-based spectrophotometric assay
|
ChEMBL.
|
22061825
|
IC50 (functional)
|
= 6.8 uM
|
Amoebicidal activity against trophozoite stage of Entamoeba histolytica HM-1:IMSS assessed as growth inhibition after 72 hrs by carboxyfluorescein diacetate/propidium iodide staining-based fluorescence microscopic analysis
|
ChEMBL.
|
No reference
|
IC50 (functional)
|
> 50 uM
|
Antileishmanial activity against Leishmania mexicana MHOM/MX/ISETGS promastigotes after 72 hrs by neubauer chamber
|
ChEMBL.
|
21397502
|
IC50 (functional)
|
> 50 uM
|
Antitrypanosomal activity against Trypanosoma cruzi MHOM/MX/1994/Ninoa epimastigotes after 72 hrs by neubauer chamber
|
ChEMBL.
|
21397502
|
IC50 (functional)
|
> 50 uM
|
Antimalarial activity against Plasmodium berghei schizonts isolated from parasitized erythrocytes infected Wistar rat measured 16 hrs post compound exposure
|
ChEMBL.
|
21397502
|
IC50 (functional)
|
> 50 uM
|
Antimicrobial activity against epimastigote stage of Trypanosoma cruzi MHOM/MX/1994/Ninoa clinical isolate after 72 hrs by Neubauer chamber analysis
|
ChEMBL.
|
24529307
|
IC50 (functional)
|
= 55.85 uM
|
Antiparasitic activity against Trichomonas vaginalis 162 after 48 hrs by MTT assay
|
ChEMBL.
|
26695730
|
IC50 (ADMET)
|
> 100 uM
|
Cytotoxicity against human KB cells after 44 hrs by MTT assay
|
ChEMBL.
|
17513021
|
IC50 (ADMET)
|
> 100 uM
|
Cytotoxicity against human KB cells after 44 hrs by MTT assay
|
ChEMBL.
|
18222017
|
IC50 (ADMET)
|
> 100 uM
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
ChEMBL.
|
20696501
|
IC50 (ADMET)
|
> 100 uM
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
ChEMBL.
|
20961670
|
IC50 (ADMET)
|
> 100 uM
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
ChEMBL.
|
21377771
|
IC50 (ADMET)
|
> 100 uM
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
ChEMBL.
|
22236470
|
IC50 (ADMET)
|
> 100 uM
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
ChEMBL.
|
22840694
|
IC50 (functional)
|
> 175.28 uM
|
DNDI: Leish (macro) in Vitro, 96 hour
|
ChEMBL.
|
No reference
|
IC50 (functional)
|
= 177.9 uM
|
Inhibition of Cav1
|
LITERATURE.
|
23812503
|
IC50 (binding)
|
> 200 uM
|
Inhibition of human CYP51 expressed in Topp 3 cells by lanosterol demethylase assay
|
ChEMBL.
|
17194716
|
IC50 (binding)
|
> 200 uM
|
Inhibition of human CYP51 expressed in Topp 3 cells by lanosterol demethylase assay
|
ChEMBL.
|
17194716
|
IC50 (ADMET)
|
> 250 uM
|
Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
|
ChEMBL.
|
22309914
|
IC50 (ADMET)
|
> 250 uM
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
ChEMBL.
|
22444681
|
IC50 (ADMET)
|
> 250 uM
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
ChEMBL.
|
22832309
|
IC50 (functional)
|
= 276.94 uM
|
DNDI: Malaria in Vitro, 72 hour
|
ChEMBL.
|
No reference
|
IC50 (functional)
|
= 278.69 uM
|
DNDI: Chagas in Vitro, 96 hour
|
ChEMBL.
|
No reference
|
IC50 (functional)
|
= 337.7 uM
|
DNDI: HAT in Vitro, 72 hour
|
ChEMBL.
|
No reference
|
IC50 (functional)
|
= 491.36 uM
|
DNDI: Leish (axenic) in Vitro, 72 hour
|
ChEMBL.
|
No reference
|
IC50 (ADMET)
|
> 500 uM
|
Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry
|
ChEMBL.
|
19748781
|
IC50 (ADMET)
|
> 1460 uM
|
Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide-based flow cytometry
|
ChEMBL.
|
18590939
|
IC50 (functional)
|
= 2.63 uM/ml
|
Antiamnesic activity against Entamoeba histolytica HM1:IMSS after 72 hrs by microdilution method
|
ChEMBL.
|
18675491
|
Inhibition (functional)
|
|
Antibacterial activity against Mycobacterium tuberculosis H37Rv at 6.25 mg/ml
|
ChEMBL.
|
16562840
|
Inhibition (binding)
|
|
Inhibition of HIV1 reverse transcriptase at 100 ug/ml incubated for 1 hr by ELISA method
|
ChEMBL.
|
26209833
|
Inhibition (binding)
|
= 17 %
|
Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate assessed as formation of prostanoid products at 500 uM preincubated for 10 mins prior to substrate addition measured after 2 mins by Ellman's method relative to control
|
ChEMBL.
|
24088053
|
Inhibition (ADMET)
|
= 98.26849409 %
|
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
ChEMBL.
|
23571415
|
Inhibition (functional)
|
= 100 %
|
Trichomonicidal activity against Trichomonas vaginalis JH31A#4 trophozite assessed as inhibition of parasite growth at 300 uM after 24 hrs by resazurin redox dye based fluorimetric microtiter method
|
ChEMBL.
|
25771033
|
Inhibition (ADMET)
|
= 102.586625 %
|
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
ChEMBL.
|
23571415
|
Inhibitory zone (functional)
|
= 0 mM
|
Antifungal activity against Saccharomyces cerevisiae, activity expressed as inhibitory zone (mm, diameter)
|
ChEMBL.
|
6834379
|
Inhibitory zone (functional)
|
= 0 mM
|
Antifungal activity against Trichophyton mentagrophytes, activity expressed as inhibitory zone (mm, diameter)
|
ChEMBL.
|
6834379
|
Inhibitory zone (functional)
|
= 0 mM
|
Antifungal activity against Candida albicans, activity expressed as minimum inhibitory zone (mm, diameter)
|
ChEMBL.
|
6834379
|
Inhibitory zone (functional)
|
= 0 mM
|
Antibacterial activity against Actinomyces israelii, activity expressed as inhibitory zone (mm, diameter)
|
ChEMBL.
|
6834379
|
Inhibitory zone (functional)
|
= 0 mM
|
Antibacterial activity against Propionibacterium acnes, activity expressed as inhibitory zone (mm, diameter)
|
ChEMBL.
|
6834379
|
Inhibitory zone (functional)
|
= 0 mM
|
Antibacterial activity against Streptococcus pyogenes C, activity expressed as inhibitory zone (mm, diameter)
|
ChEMBL.
|
6834379
|
Inhibitory zone (functional)
|
= 0 mM
|
Antifungal activity against Saccharomyces cerevisiae, activity expressed as inhibitory zone (mm, diameter)
|
ChEMBL.
|
6834379
|
Inhibitory zone (functional)
|
= 0 mM
|
Antifungal activity against Candida albicans, activity expressed as minimum inhibitory zone (mm, diameter)
|
ChEMBL.
|
6834379
|
Inhibitory zone (functional)
|
= 8 mM
|
Antifungal activity against Epidermophyton floccosum, activity expressed as inhibitory zone (mm, diameter)
|
ChEMBL.
|
6834379
|
Inhibitory zone (functional)
|
= 20 mM
|
Antibacterial activity against Bacteroides fragilis, activity expressed as minimum inhibitory zone (mm, diameter)
|
ChEMBL.
|
6834379
|
Inhibitory zone (functional)
|
= 25 mM
|
Antibacterial activity against Clostridium novyi, activity expressed as inhibitory zone (mm, diameter)
|
ChEMBL.
|
6834379
|
IZ (functional)
|
= 15 mm
|
Antimicrobial activity against Candida albicans at 50 ug/mL after 72 hrs by well plate method
|
ChEMBL.
|
20813436
|
IZ (functional)
|
= 19.5 mm
|
Antimicrobial activity against Candida albicans at 100 ug/mL after 72 hrs by well plate method
|
ChEMBL.
|
20813436
|
Ki (binding)
|
|
DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA))
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon))
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Chemokine CXCR1 (IL-8A)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
|
DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid)
|
ChEMBL.
|
No reference
|
Ki (binding)
|
= 3.3 uM
|
Inhibition of Entamoeba histolytica thioredoxin reductase
|
LITERATURE.
|
27597415
|
Km (functional)
|
0 ug ml-1
|
Stability towards beta-lactamase was determined in Bacillus fragilis FP784; Not tested
|
ChEMBL.
|
15109666
|
Km (functional)
|
0 ug ml-1
|
Stability towards penicillinase was determined; Not tested
|
ChEMBL.
|
15109666
|
LD50 (ADMET)
|
= 3800 mg kg-1
|
Acute toxicity in po dosed mouse
|
ChEMBL.
|
199729
|
Log BR (ADMET)
|
= 2.407
|
The total 18 h urinary excretion of the unchanged form of compound in urine was reported as log (percent X 10) of the administered dose by HPLC technique
|
ChEMBL.
|
3959031
|
Log BR (ADMET)
|
= 2.484
|
The total 18 h urinary excretion of unchanged compound reported as log (percent X 10) of the administered dose
|
ChEMBL.
|
3959031
|
Log BR (ADMET)
|
= 2.692
|
The total 36 h urinary excretion of unchanged compound reported as log (percent X 10) of the administered dose
|
ChEMBL.
|
3959031
|
Log BR (ADMET)
|
= 2.692
|
The total 54 h urinary excretion of unchanged compound reported as log (percent X 10) of the administered dose
|
ChEMBL.
|
3959031
|
Log BR (ADMET)
|
= 2.692
|
The total 72 h urinary excretion of unchanged compound reported as log (percent X 10) of the administered dose
|
ChEMBL.
|
3959031
|
Log k' (ADMET)
|
= -0.067
|
Capacity factor (log k')
|
ChEMBL.
|
3959031
|
Log K'w (ADMET)
|
= -0.32
|
HPLC capacity factor (k)
|
ChEMBL.
|
10956200
|
Log Pmic |
= 0.54
|
Micelle/water partition coefficient (Pmic) of the compund was determined
|
ChEMBL.
|
8691461
|
log10cfu (functional)
|
= 2.8
|
Antimicrobial activity against log phase recombinant Mycobacterium tuberculosis H37Rv-lux with plasmid MV361 at 10 ug/ml incubated for 7 days assessed as bacterial count
|
ChEMBL.
|
10879539
|
log10cfu (functional)
|
= 3.2
|
Antimicrobial activity against log phase recombinant Mycobacterium tuberculosis H37Rv-lux with plasmid MV361 at 10 ug/ml incubated for 7 days assessed as bacterial count after 4 days
|
ChEMBL.
|
10879539
|
log10CFU/ml (functional)
|
= 1.16
|
Bactericidal activity against non-replicating Mycobacterium tuberculosis H37Rv Wayne model under hypoxic/oxygen depleted conditions assessed as log reduction at 50 ug/ml after 4 days by serial dilution assay
|
ChEMBL.
|
25614114
|
logD (ADMET)
|
= -0.02
|
Partition coefficient (logD7.4)
|
ChEMBL.
|
11448232
|
logD (ADMET)
|
= -0.02
|
Partition coefficient (logD6.5)
|
ChEMBL.
|
10891117
|
logP (ADMET)
|
= -0.22
|
Partition coefficient (logP) (HPLC)
|
ChEMBL.
|
10956200
|
logP (ADMET)
|
= -0.16
|
Partition coefficient (logP)
|
ChEMBL.
|
7392035
|
logP (ADMET)
|
= -0.1
|
Partition coefficient (logP)
|
ChEMBL.
|
3806622
|
logP (ADMET)
|
= -0.1
|
Partition coefficient (logP)
|
ChEMBL.
|
3959031
|
logP (ADMET)
|
= -0.02
|
Partition coefficient (logP)
|
ChEMBL.
|
1995902
|
logP (ADMET)
|
= -0.02
|
Partition coefficient (logP)
|
ChEMBL.
|
10956200
|
MAC (functional)
|
|
Antiprotozoal activity against Trypanosoma brucei brucei GVR35
|
ChEMBL.
|
16309903
|
MAC (functional)
|
0
|
Antiprotozoal activity against Trypanosoma brucei brucei GVR35
|
ChEMBL.
|
16309903
|
MAC (functional)
|
= 62.5 uM
|
Antimycobacterial activity against wild type Mycobacterium tuberculosis H37Rv NRP-2 stage after 3 weeks under anaerobic condition
|
ChEMBL.
|
19209889
|
MAC (functional)
|
= 125 uM
|
Antimycobacterial activity against Mycobacterium tuberculosis with deazaflavin-dependent nitroreductase mutant under anaerobic condition
|
ChEMBL.
|
19209889
|
MBC (functional)
|
= 2 ug ml-1
|
Minimum bactericidal concentration against Helicobacter pylori ATCC 43504; range 2-4 ug/mL
|
ChEMBL.
|
12213070
|
MEC (functional)
|
= 2 ug ml-1
|
Trichomonacidal activity against Trichomonas vaginalis after 48 hrs by trypan blue exclusion assay
|
ChEMBL.
|
24140949
|
MED (functional)
|
= 10 mg kg-1
|
Antimicrobial activity against Entamoeba histolytica NIH 200-mu cecal forms infected in Wistar albino rat assessed as cure rate administered qd for 5 days by microscopic analysis
|
ChEMBL.
|
203694
|
MIC (functional)
|
|
Antibacterial activity against Escherichia coli ATCC 25922 by standard broth microdilution technique
|
ChEMBL.
|
16562840
|
MIC (functional)
|
= 0.006 mM
|
Minimum inhibitory concentration measured against B. fragilis strain
|
ChEMBL.
|
3339605
|
MIC (functional)
|
= 0.013 mM
|
Minimum inhibitory concentration measured against C. perfringens strain
|
ChEMBL.
|
3339605
|
MIC (functional)
|
= 0.1 mM
|
Minimum inhibitory concentration measured against E. coli SR58 strain (RecA- UvrB-)
|
ChEMBL.
|
3339605
|
MIC (functional)
|
= 0.1 mM
|
Minimum inhibitory concentration measured against E. coli SR58 strain (RecA- UvrB-)
|
ChEMBL.
|
3339605
|
MIC (functional)
|
> 0.5 mM
|
Minimum inhibitory concentration measured against E. coli AB1157 strain (Uvr+ Rec+)
|
ChEMBL.
|
3339605
|
MIC (functional)
|
> 0.5 mM
|
Minimum inhibitory concentration measured against E. coli AB1885 strain (UvrB- Rec+)
|
ChEMBL.
|
3339605
|
MIC (functional)
|
> 0.5 mM
|
Minimum inhibitory concentration measured against E. coli AB1157 strain (Uvr+ Rec+)
|
ChEMBL.
|
3339605
|
MIC (functional)
|
> 0.5 mM
|
Minimum inhibitory concentration measured against E. coli AB1885 strain (UvrB- Rec+)
|
ChEMBL.
|
3339605
|
MIC (functional)
|
= 0.6 mM
|
Minimum inhibitory concentration measured against E. coli EE128 strain (Uvr+ RecA-)
|
ChEMBL.
|
3339605
|
MIC (functional)
|
> 0.6 mM
|
Minimum inhibitory concentration measured against E. coli EE349 strain (UvrB- Rec+)
|
ChEMBL.
|
3339605
|
MIC (functional)
|
= 0.6 mM
|
Minimum inhibitory concentration measured against E. coli EE128 strain (Uvr+ RecA-)
|
ChEMBL.
|
3339605
|
MIC (functional)
|
> 0.6 mM
|
Minimum inhibitory concentration measured against E. coli EE349 strain (UvrB- Rec+)
|
ChEMBL.
|
3339605
|
MIC (functional)
|
= 5.48 mM
|
Antibacterial activity against Escherichia coli ATCC 8739 after 24 hr by broth microdilution method
|
ChEMBL.
|
No reference
|
MIC (functional)
|
= 0.031 ug ml-1
|
Minimal concentration needed to inhibitH. pylori strain
|
ChEMBL.
|
11212121
|
MIC (functional)
|
= 0.098 ug ml-1
|
Antimicrobial activity against Trichomonas vaginalis ATCC 30001 assessed as growth inhibition after 48 hrs under anaerobic conditions by microscopic analysis
|
ChEMBL.
|
25969
|
MIC (functional)
|
= 0.2 ug ml-1
|
Antimicrobial activity was measured against C. difficile organism; Value ranges from 0.1-0.39
|
ChEMBL.
|
10966750
|
MIC (functional)
|
= 0.2 ug ml-1
|
Compound was evaluated for antimicrobial activity against C. difficile
|
ChEMBL.
|
9871756
|
MIC (functional)
|
= 0.25 ug ml-1
|
Antimicrobial activity against Trichomonas vaginalis
|
ChEMBL.
|
9083486
|
MIC (functional)
|
= 0.25 ug ml-1
|
Antimicrobial activity against Trichomonas vaginalis
|
ChEMBL.
|
9083486
|
MIC (functional)
|
= 0.5 ug ml-1
|
Antibacterial activity against Bacteroides fragilis after 20 hrs by broth microdilution method
|
ChEMBL.
|
17442577
|
MIC (functional)
|
= 0.5 ug ml-1
|
Antiprotozoal activity against Trichomonas vaginalis assessed as static effect
|
ChEMBL.
|
199729
|
MIC (functional)
|
= 0.54 ug ml-1
|
Antitrichomonas activity against Trichomonas vaginalis after 48 hrs by trypan blue staining
|
ChEMBL.
|
18061311
|
MIC (functional)
|
= 0.59 ug ml-1
|
Antimicrobial activity was measured against B. fragilisrange; Value ranges from 0.39-0.78
|
ChEMBL.
|
10966750
|
MIC (functional)
|
= 0.59 ug ml-1
|
Compound was evaluated for antimicrobial activity against B. fragilis
|
ChEMBL.
|
9871756
|
MIC (functional)
|
< 0.8 ug ml-1
|
Minimum inhibitory concentration of the compound was determined against Bacteroides fragilis(NCTC 10581)(in vitro)
|
ChEMBL.
|
1875335
|
MIC (functional)
|
< 0.8 ug ml-1
|
Minimum inhibitory concentration of the compound was determined against Bacteroides fragilis(NCTC 9343)(in vitro)
|
ChEMBL.
|
1875335
|
MIC (functional)
|
< 0.8 ug ml-1
|
Minimum inhibitory concentration of the compound was determined against Bacteroides fragilis(NCTC 9344)(in vitro)
|
ChEMBL.
|
1875335
|
MIC (functional)
|
< 0.8 ug ml-1
|
Minimum inhibitory concentration of the compound was determined against Clostridium perfringens(NCTC 523)(in vitro)
|
ChEMBL.
|
1875335
|
MIC (functional)
|
< 0.8 ug ml-1
|
Minimum inhibitory concentration of the compound was determined against Clostridium perfringens(NCTC 8237)(in vitro)
|
ChEMBL.
|
1875335
|
MIC (functional)
|
< 0.8 ug ml-1
|
Minimum inhibitory concentration of the compound was determined against Fusobacterium necrophorum (ATCC 11295)(in vitro)
|
ChEMBL.
|
1875335
|
MIC (functional)
|
< 0.8 ug ml-1
|
Minimum inhibitory concentration of the compound was determined against Peptococcus magnus(in vitro)
|
ChEMBL.
|
1875335
|
MIC (functional)
|
< 0.8 ug ml-1
|
Minimum inhibitory concentration of the compound was determined against Peptostreptococcus anaerobius(in vitro)
|
ChEMBL.
|
1875335
|
MIC (functional)
|
= 1 ug ml-1
|
Minimum inhibitory concentration against Helicobacter pylori (H. pylori) ARHp strain 81
|
ChEMBL.
|
12213071
|
MIC (functional)
|
= 1 ug ml-1
|
Minimum inhibitory concentration against Helicobacter pylori (H. pylori) ARHp strain 115
|
ChEMBL.
|
12213071
|
MIC (functional)
|
= 1 ug ml-1
|
Minimum inhibitory concentration against Helicobacter pylori (H. pylori) ARHp strain 206
|
ChEMBL.
|
12213071
|
MIC (functional)
|
= 1 ug ml-1
|
Antibacterial activity against Bacteroides thetaiotaomicron after 20 hrs by broth microdilution method
|
ChEMBL.
|
17442577
|
MIC (functional)
|
= 1.5 ug ml-1
|
Minimum inhibitory concentration of the compound was determined against Bacteroides fragilis(WSI)(in vitro)
|
ChEMBL.
|
1875335
|
MIC (functional)
|
= 1.5 ug ml-1
|
Minimum inhibitory concentration of the compound was determined against Peptococcus prevotti(in vitro)
|
ChEMBL.
|
1875335
|
MIC (functional)
|
= 1.56 ug ml-1
|
Antitrichomonal activity against metronidazole-susceptible Trichomonas vaginalis clinical isolate by trypan blue staining-based cell counting
|
ChEMBL.
|
24727243
|
MIC (functional)
|
= 1.75 ug ml-1
|
Antimicrobial activity was measured against C. perfringens organism; Value ranges from 0.78-3.13
|
ChEMBL.
|
10966750
|
MIC (functional)
|
= 1.75 ug ml-1
|
Compound was evaluated for antimicrobial activity against C. perfringens
|
ChEMBL.
|
9871756
|
MIC (functional)
|
= 2 ug ml-1
|
Antibacterial activity of the compound against Helicobacter pylori HP003 was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
= 2 ug ml-1
|
Antitrichomonas activity against Trichomonas vaginalis after 48 hrs by trypan blue exclusion assay
|
ChEMBL.
|
21130651
|
MIC (functional)
|
= 2 ug ml-1
|
Antimicrobial activity against clinical isolate of Trichomonas vaginalis
|
ChEMBL.
|
22846917
|
MIC (functional)
|
= 4 ug ml-1
|
Antibacterial activity of the compound against Helicobacter pylori HP001 was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
= 5 ug ml-1
|
Antimicrobial activity against Trichomonas vaginalis by broth dilution method
|
ChEMBL.
|
211235
|
MIC (functional)
|
= 5.4 ug ml-1
|
The lowest drug concentration that inhibited macroscopic colonial growth against Helicobacter pylori; Value ranges from 1.56-25
|
ChEMBL.
|
10966750
|
MIC (functional)
|
= 5.4 ug ml-1
|
Minimum inhibitory concentration required to inhibit macroscopic colonial growth of Helicobacter pylori ; ranges from(1.56-25)
|
ChEMBL.
|
11754586
|
MIC (functional)
|
= 5.4 ug ml-1
|
Minimum inhibitory concentration that inhibited macroscopic colony growth of Helicobacter pylori
|
ChEMBL.
|
10425101
|
MIC (functional)
|
= 5.4 ug ml-1
|
Evaluated for antimicrobial activity against H. pylori
|
ChEMBL.
|
9258352
|
MIC (functional)
|
= 5.4 ug ml-1
|
Compound was evaluated for antimicrobial activity against Helicobacter pylori
|
ChEMBL.
|
9871756
|
MIC (functional)
|
= 6.2 ug ml-1
|
Minimum inhibitory concentration of the compound was determined against Bacteroides fragilis(MZ-R)(in vitro)
|
ChEMBL.
|
1875335
|
MIC (functional)
|
= 8 ug ml-1
|
Antibacterial activity of the compound against Helicobacter pylori HP004 was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
= 8 ug ml-1
|
Antibacterial activity of the compound against Helicobacter pylori HP0018 was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
= 8 ug ml-1
|
Inhibitory activity was determined against 102R strain of H. pylori
|
ChEMBL.
|
11212121
|
MIC (functional)
|
= 8 ug ml-1
|
Minimum inhibitory concentration against Helicobacter pylori (H. pylori) ARHp strain 80
|
ChEMBL.
|
12213071
|
MIC (functional)
|
= 10 ug ml-1
|
Antibacterial activity against Trichomonas vaginalis ATCC 30001 after 48 hrs by ten-fold serial dilution method
|
ChEMBL.
|
412966
|
MIC (functional)
|
= 16 ug ml-1
|
Antibacterial activity of the compound against Helicobacter pylori HP007 was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
= 16 ug ml-1
|
Antibacterial activity of the compound against Helicobacter pylori HP022 was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
= 16 ug ml-1
|
Inhibitory activity was determined against NCTC11637 strain of H. pylori
|
ChEMBL.
|
11212121
|
MIC (functional)
|
= 25 ug ml-1
|
Minimum inhibitory activity of the compound was determined against clarithromycin- and metronidazole-resistant strain 15069
|
ChEMBL.
|
15109666
|
MIC (functional)
|
= 30 ug ml-1
|
Antimicrobial activity was measured against C. jejuni organism; Value ranges from 0.78-100
|
ChEMBL.
|
10966750
|
MIC (functional)
|
= 30 ug ml-1
|
Compound was evaluated for antimicrobial activity against C. jejuni
|
ChEMBL.
|
9871756
|
MIC (functional)
|
= 32 ug ml-1
|
Antibacterial activity of the compound against Helicobacter pylori HP008 was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
= 32 ug ml-1
|
Antibacterial activity of the compound against Helicobacter pylori HP0016 was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
= 32 ug ml-1
|
Antibacterial activity of the compound against Helicobacter pylori HP0019 was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
= 32 ug ml-1
|
Antibacterial activity of the compound against Helicobacter pylori HP021 was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
> 32 ug ml-1
|
Antifungal activity against Saccharomyces cerevisiae, activity expressed as minimum inhibitory concentration (ug/mL).
|
ChEMBL.
|
6834379
|
MIC (functional)
|
> 32 ug ml-1
|
Antifungal activity against Trichophyton mentagrophytes, activity expressed as minimum inhibitory concentration (ug/mL).
|
ChEMBL.
|
6834379
|
MIC (functional)
|
> 32 ug ml-1
|
Antifungal activity against Candida albicans, activity expressed as minimum inhibitory concentration (ug/mL)
|
ChEMBL.
|
6834379
|
MIC (functional)
|
> 32 ug ml-1
|
Antifungal activity against Epidermophyton floccosum, activity expressed as minimum inhibitory concentration (ug/mL)
|
ChEMBL.
|
6834379
|
MIC (functional)
|
> 32 ug ml-1
|
Antifungal activity against Saccharomyces cerevisiae, activity expressed as minimum inhibitory concentration (ug/mL).
|
ChEMBL.
|
6834379
|
MIC (functional)
|
> 32 ug ml-1
|
Antifungal activity against Candida albicans, activity expressed as minimum inhibitory concentration (ug/mL)
|
ChEMBL.
|
6834379
|
MIC (functional)
|
= 50 ug ml-1
|
Minimum inhibitory activity of the compound was determined against clarithromycin- and metronidazole-resistant strain 16021
|
ChEMBL.
|
15109666
|
MIC (functional)
|
= 50 ug ml-1
|
Minimum inhibitory activity of the compound was determined against clarithromycin- and metronidazole-resistant strain 16043
|
ChEMBL.
|
15109666
|
MIC (functional)
|
> 50 ug ml-1
|
Antibacterial activity against Escherichia coli ATCC 700927 assessed as growth inhibition after 20 to 24 hrs
|
ChEMBL.
|
24360560
|
MIC (functional)
|
= 64 ug ml-1
|
Antibacterial activity of the compound against Helicobacter pylori ATCC43504 was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
= 64 ug ml-1
|
Antibacterial activity of the compound against Helicobacter pylori HP0017 was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
= 64 ug ml-1
|
Minimal inhibitory concentration of the compound against metronidazole resistant Helicobacter pylori NCTC 11637 strain
|
ChEMBL.
|
15664821
|
MIC (functional)
|
= 64 ug ml-1
|
Minimal inhibitory concentration of the compound against metronidazole resistant Helicobacter pylori 8 strain
|
ChEMBL.
|
15664821
|
MIC (functional)
|
= 64 ug ml-1
|
Minimal inhibitory concentration of the compound against metronidazole resistant Helicobacter pylori 19 strain
|
ChEMBL.
|
15664821
|
MIC (functional)
|
= 64 ug ml-1
|
Minimal inhibitory concentration of the compound against metronidazole resistant Helicobacter pylori 20 strain
|
ChEMBL.
|
15664821
|
MIC (functional)
|
> 100 ug ml-1
|
Antimicrobial activity was measured against N. gonorrheas organism
|
ChEMBL.
|
10966750
|
MIC (functional)
|
> 100 ug ml-1
|
Antimicrobial activity was measured against N. meningitidis organism.
|
ChEMBL.
|
10966750
|
MIC (functional)
|
> 100 ug ml-1
|
Antibacterial activity of the compound against Staphylococcus aureus 209P JC was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
> 100 ug ml-1
|
Antibacterial activity of the compound against Staphylococcus epidermidis was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
> 100 ug ml-1
|
Antibacterial activity of the compound against Enterococcus faecalis was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
> 100 ug ml-1
|
Antibacterial activity of the compound against Escherichia coli K-12 was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
> 100 ug ml-1
|
Antibacterial activity of the compound against Klebsiella pneumoniae was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
> 100 ug ml-1
|
Antibacterial activity of the compound against Morganella morganii was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
> 100 ug ml-1
|
Minimum inhibitory concentration of the compound was determined against Propionibacterium acnes(NCTC 737)(in vitro)
|
ChEMBL.
|
1875335
|
MIC (functional)
|
> 100 ug ml-1
|
Minimum inhibitory concentration of the compound was determined against Propionibacterium acnes(NCTC 7337)(in vitro)
|
ChEMBL.
|
1875335
|
MIC (functional)
|
> 100 ug ml-1
|
Compound was evaluated for antimicrobial activity against N. gonorrhoea
|
ChEMBL.
|
9871756
|
MIC (functional)
|
> 100 ug ml-1
|
Compound was evaluated for antimicrobial activity against N. meningitidis
|
ChEMBL.
|
9871756
|
MIC (functional)
|
> 100 ug ml-1
|
Antibacterial activity of the compound against Escherichia coli K-12 was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
= 128 ug ml-1
|
Antibacterial activity of the compound against Helicobacter pylori HP020 was determined
|
ChEMBL.
|
12873498
|
MIC (functional)
|
> 200 ug ml-1
|
Antimicrobial activity against Helicobacter pylori DSMZ 4867
|
ChEMBL.
|
16945527
|
MIC (functional)
|
> 300 ug ml-1
|
Antibacterial activity against Escherichia coli SKF 12140 assessed as growth inhibition
|
ChEMBL.
|
199729
|
MIC (functional)
|
= 2.92 uM
|
Antiparasitic activity against Trichomonas vaginalis GT3 after 48 hr by Alamar blue assay
|
ChEMBL.
|
No reference
|
MIC (functional)
|
= 2.92 uM
|
Antiparasitic activity against Trichomonas vaginalis GT3 after 24 hr by Alamar blue assay
|
ChEMBL.
|
No reference
|
MIC (functional)
|
= 5 uM
|
Antitrichomonal activity against Trichomonas vaginalis after 48 hrs by invert microscope analysis
|
ChEMBL.
|
26099536
|
MIC (functional)
|
= 11.6 uM
|
Antitrichomonas activity against trophozoite stage of Trichomonas vaginalis clinical isolate assessed as cell viability under anaerobic condition after 48 hrs by trypan blue exclusion assay
|
ChEMBL.
|
27084496
|
MIC (functional)
|
= 11.7 uM
|
Antitrichomonal activity against Trichomonas vaginalis after 48 hrs by trypan blue exclusion assay
|
ChEMBL.
|
19906466
|
MIC (functional)
|
= 19.71 uM
|
Anti-trichomonas activity against MTZ-susceptible Trichomonas vaginalis incubated for 3 to 48 hrs by trypan blue exclusion assay
|
ChEMBL.
|
26209833
|
MIC (functional)
|
= 40 uM
|
Antimicrobial activity against nonreplicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days
|
ChEMBL.
|
17210775
|
MIC (functional)
|
= 40 uM
|
Antimicrobial activity against nonreplicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days
|
ChEMBL.
|
17210775
|
MIC (functional)
|
> 100 uM
|
Antimycobacterial activity against Mycobacterium tuberculosis with cofactor F420 mutant
|
ChEMBL.
|
19209889
|
MIC (functional)
|
> 100 uM
|
Antimycobacterial activity against Mycobacterium tuberculosis with deazaflavin-dependent nitroreductase mutant
|
ChEMBL.
|
19209889
|
MIC (functional)
|
> 128 uM
|
Antimicrobial activity against nonreplicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days
|
ChEMBL.
|
17210775
|
MIC (functional)
|
> 128 uM
|
Antimicrobial activity against nonreplicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days
|
ChEMBL.
|
17210775
|
MIC (functional)
|
> 128 uM
|
Antimicrobial activity against nonreplicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay
|
ChEMBL.
|
17210775
|
MIC (functional)
|
> 128 uM
|
Antimicrobial activity against nonreplicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days
|
ChEMBL.
|
17210775
|
MIC (functional)
|
> 128 uM
|
Antimicrobial activity against nonreplicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days
|
ChEMBL.
|
17210775
|
MIC (functional)
|
> 128 uM
|
Antimicrobial activity against nonreplicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay
|
ChEMBL.
|
17210775
|
MIC (functional)
|
> 300 uM
|
Antimycobacterial activity against wild type Mycobacterium tuberculosis H37Rv ATCC 27294 after 2 weeks
|
ChEMBL.
|
19209889
|
MIC (functional)
|
= 747.7 uM
|
Antibacterial activity against Helicobacter pylori ATCC43504 by agar dilution method
|
ChEMBL.
|
17883259
|
MIC (functional)
|
= 1.46 uM l-1
|
Minimum inhibitory concentration(MIC) of compound expressed as geometric mean of various bacterias.*
|
ChEMBL.
|
No reference
|
MIC (functional)
|
= 11.7 umol
|
Antitrichomonas activity against metronidazole-susceptible Trichomonas vaginalis
|
ChEMBL.
|
24900434
|
MIC100 (functional)
|
|
Bactericidal activity against non-replicating Mycobacterium tuberculosis H37Rv Wayne model under hypoxic/oxygen depleted conditions assessed as log reduction after 4 days by serial dilution assay
|
ChEMBL.
|
25614114
|
MIC50 (functional)
|
< 0.016 ug ml-1
|
Antibacterial activity against Peptostreptococcus stomatis
|
ChEMBL.
|
17403999
|
MIC50 (functional)
|
= 0.094 ug ml-1
|
Antibacterial activity against Peptostreptococcus anaerobius
|
ChEMBL.
|
17403999
|
MIC50 (functional)
|
= 0.25 ug ml-1
|
Minimal concentration needed to inhibit 50% of H. pylori strain
|
ChEMBL.
|
11212121
|
MIC50 (functional)
|
= 0.5 ug ml-1
|
Minimal inhibitory concentration of the compound against 17 strains of Helicobacter pylori
|
ChEMBL.
|
15664821
|
MIC50 (functional)
|
= 0.5 ug ml-1
|
Antibacterial activity against Clostridium difficile by agar dilution method
|
ChEMBL.
|
17242152
|
MIC50 (functional)
|
= 2 ug ml-1
|
Antibacterial activity against Bacteroides fragilis by agar dilution method
|
ChEMBL.
|
17242152
|
MIC50 (functional)
|
> 64 ug ml-1
|
Antibacterial activity against Propionibacterium acnes
|
ChEMBL.
|
17242152
|
MIC50 (functional)
|
= 74 ug ml-1
|
In vitro inhibitory activity evaluated against Helicobacter pylori (HP)
|
ChEMBL.
|
10021926
|
MIC90 (functional)
|
= 0.047 ug ml-1
|
Antibacterial activity against Peptostreptococcus stomatis
|
ChEMBL.
|
17403999
|
MIC90 (functional)
|
= 0.19 ug ml-1
|
Antibacterial activity against Peptostreptococcus anaerobius
|
ChEMBL.
|
17403999
|
MIC90 (functional)
|
= 0.5 ug ml-1
|
Antibacterial activity against Clostridium difficile by agar dilution method
|
ChEMBL.
|
17242152
|
MIC90 (functional)
|
= 1 ug ml-1
|
Antibacterial activity against Bacteroides fragilis by agar dilution method
|
ChEMBL.
|
17242152
|
MIC90 (functional)
|
= 8 ug ml-1
|
Minimal concentration needed to inhibit 90% of H. pylori strain
|
ChEMBL.
|
11212121
|
MIC90 (functional)
|
> 10 ug ml-1
|
Antitubercular activity against Mycobacterium tuberculosis H37Rv isolate SRI after 5 days by resazurin-based microplate assay
|
ChEMBL.
|
22691154
|
MIC90 (functional)
|
= 11 ug ml-1
|
Antitubercular activity against Mycobacterium tuberculosis H37Rv incubated for 10 days in anaerobic condition followed by 48 hrs incubation in aerobic condition by LORA assay
|
ChEMBL.
|
22691154
|
MIC90 (functional)
|
> 32 ug ml-1
|
Antitubercular activity against Mycobacterium tuberculosis H37Rv isolate ITR after 7 days by luminescence spectrometry
|
ChEMBL.
|
22691154
|
MIC90 (functional)
|
= 64 ug ml-1
|
Minimal inhibitory concentration of the compound against 17 strains of Helicobacter pylori
|
ChEMBL.
|
15664821
|
MIC90 (functional)
|
> 64 ug ml-1
|
Antibacterial activity against Propionibacterium acnes
|
ChEMBL.
|
17242152
|
MIC>90 (functional)
|
= 5.3 ug ml-1
|
Antimycobacterial activity against Mycobacterium tuberculosis harboring luxABCDE under hypoxic condition after 10 days by MABA assay in presence of 10% fetal bovine serum
|
ChEMBL.
|
24224794
|
Mutagenicity (functional)
|
+ 0
|
Compound was tested for the mutagenicity activity in the Salmonella typhimurium reverse mutation assay; +++-indicates the levels of mutagencity as the number of revertant colonies obtained increases 10 times
|
ChEMBL.
|
No reference
|
Mutagenicity (functional)
|
= 7 %
|
The Mutagenicity against Trichomonas foetus relative to Ronidazole.
|
ChEMBL.
|
3543363
|
NC (ADMET)
|
0
|
AUC (area under curve) after oral dosing by gavage needle at 30 mg/kg in C57BL/6NTac female mice; Not checked
|
ChEMBL.
|
12213071
|
NC (ADMET)
|
0
|
Maximum plasma concentration (Cmax) after oral dosing by gavage needle at 30 mg/kg in C57BL/6NTac female mice; Not checked
|
ChEMBL.
|
12213071
|
ND (functional)
|
0
|
Inhibition of histamine-stimulated gastric acid secretion in lumen-perfused stomach of anesthetized rats after 1 mg/kg iv administration ;ND is No Data.
|
ChEMBL.
|
11754586
|
ND (functional)
|
0
|
Inhibition of histamine-stimulated chronotropic response in isolated guinea pig right atrium at 1*10e-6 g/mL ;ND is No Data.
|
ChEMBL.
|
11754586
|
Pc (functional)
|
= 0.000014 cm s-1
|
The capillary permeability of radioligand was measured in Rat brain
|
ChEMBL.
|
7392035
|
pKa |
NA 0
|
Ionisation constant (pKa)
|
ChEMBL.
|
12061889
|
pKa |
NA 0
|
Dissociation constant (pKa)
|
ChEMBL.
|
14971904
|
pKa |
ND 0
|
Dissociation constant (pKa)
|
ChEMBL.
|
10891117
|
Potency (functional)
|
0.631 uM
|
PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory)
|
ChEMBL.
|
No reference
|
Potency (functional)
|
= 2.5119 um
|
PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory)
|
ChEMBL.
|
No reference
|
Potency (functional)
|
4.0995 uM
|
PUBCHEM_BIOASSAY: qHTS of small molecules that selectively kill Giardia lamblia: Hit Validation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540272]
|
ChEMBL.
|
No reference
|
Potency (functional)
|
4.5997 uM
|
PUBCHEM_BIOASSAY: qHTS of small molecules that selectively kill Giardia lamblia: Hit Validation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540272]
|
ChEMBL.
|
No reference
|
Potency (functional)
|
= 7.0795 um
|
PUBCHEM_BIOASSAY: Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2. (Class of assay: confirmatory)
|
ChEMBL.
|
No reference
|
Potency (functional)
|
= 7.9433 um
|
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))]
|
ChEMBL.
|
No reference
|
Potency (functional)
|
7.9433 uM
|
PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory)
|
ChEMBL.
|
No reference
|
Potency (functional)
|
= 8.9125 um
|
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF. (Class of assay: confirmatory) [Related pubchem assays: 995 ]
|
ChEMBL.
|
No reference
|
Potency (functional)
|
= 15.8489 um
|
PUBCHEM_BIOASSAY: qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor. (Class of assay: confirmatory)
|
ChEMBL.
|
No reference
|
Potency (functional)
|
= 15.8489 um
|
PUBCHEM_BIOASSAY: qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293. (Class of assay: confirmatory)
|
ChEMBL.
|
No reference
|
Potency (functional)
|
= 15.8489 um
|
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF. (Class of assay: confirmatory) [Related pubchem assays: 995 ]
|
ChEMBL.
|
No reference
|
Potency (binding)
|
25.1189 uM
|
PubChem BioAssay. qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding. (Class of assay: confirmatory)
|
ChEMBL.
|
No reference
|
Potency (functional)
|
63.0957 uM
|
PUBCHEM_BIOASSAY: Inhibitors of the vitamin D receptor (VDR): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504855]
|
ChEMBL.
|
No reference
|
Potency (binding)
|
79.4328 uM
|
PubChem BioAssay. qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding. (Class of assay: confirmatory)
|
ChEMBL.
|
No reference
|
pTD50 (functional)
|
= 2.553
|
Anticarcinogenic activity in rat assessed as induction of tumors per day
|
ChEMBL.
|
18295489
|
Ratio (functional)
|
0
|
Relative stability towards beta-lactamase was determined in Bacillus fragilis FP784; Not tested
|
ChEMBL.
|
15109666
|
Ratio (functional)
|
0
|
Relative stability towards penicillinase was determined; Not tested
|
ChEMBL.
|
15109666
|
Ratio (functional)
|
= 1.6
|
Enhancement ratio was calculated to determine the radiosensitization as the ratio of radiation dose required to kill similar cells in anoxia to those with the compound; at a concentration of ~5 mM
|
ChEMBL.
|
No reference
|
Ratio (functional)
|
= 5
|
The ratio of aerobic CT10 to hypoxic CT10
|
ChEMBL.
|
8308864
|
Ratio EC50 (functional)
|
|
Selectivity ratio of EC50 for Trypanosoma brucei NfxR1 to EC50 for Trypanosoma brucei
|
ChEMBL.
|
20439607
|
Ratio EC50 (functional)
|
|
Selectivity ratio of EC50 for Trypanosoma brucei NfxR2 to EC50 for Trypanosoma brucei
|
ChEMBL.
|
20439607
|
Reduction (functional)
|
0 %
|
Percentage viability reduction of Trichinella spiralis muscle larvae after 3 days of incubation; Not determined
|
ChEMBL.
|
12127542
|
Safety index (functional)
|
= 14.3
|
Safety index.
|
ChEMBL.
|
3543363
|
Solubility |
= -0.8
|
Solubility in mMol was measured by UV spectrophotometry.
|
ChEMBL.
|
8308864
|
T1/2 (ADMET)
|
> 20 hr
|
Half life for the nitro group loss in xanthine oxidase enzyme assay in 0.2%DMF at 0.1 mM
|
ChEMBL.
|
8289205
|
TD50 (functional)
|
= 356.989 umol/Kg
|
Anticarcinogenic activity in rat assessed as induction of tumors per day
|
ChEMBL.
|
18295489
|
TI (ADMET)
|
= 1.7
|
In vitro therapeutic index of the compound (aerobic IC50 / hypoxic C1.6)
|
ChEMBL.
|
8308864
|
Uptake ratio (functional)
|
= 1.3
|
Ratio of mean intracellular to extracellular compound concentration determined under hypoxic conditions 30 mins after exposure to compound at C1.6 concentration
|
ChEMBL.
|
8308864
|
Vdss (ADMET)
|
= 0.74 l kg-1
|
Volume of distribution in man (IV dose)
|
ChEMBL.
|
12061889
|
Vdss (ADMET)
|
= 0.74 l kg-1
|
Observed volume of distribution
|
ChEMBL.
|
14971904
|
Vdss (ADMET)
|
= 0.4 L/Kg
|
Volume of distribution at steady state in human
|
ChEMBL.
|
20070106
|
Vmax (functional)
|
0
|
Stability towards beta-lactamase was determined in Bacillus fragilis FP784; Not tested
|
ChEMBL.
|
15109666
|
Vmax (functional)
|
0
|
Stability towards beta-lactamase was determined in penicillinase; Not tested
|
ChEMBL.
|
15109666
|